Natera at the 2025 ASCO Annual Meeting
Learn about our expanding body of data in solid tumor malignancies to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31-June 3, 2025.
- Over 25 presentations include nearly 25,000 patients across multiple indications, showcasing the clinical impact of Signatera™
- Significant breast cancer data to be shared in 8 abstracts including 4 oral presentations
- Large-scale, pan-cancer performance of Signatera™ Genome assay
- Significance of Signatera™ MRD and dynamics across GI, GU, Skin, Sarcoma to predict recurrence, progression, and treatment response
Shaping the future of MRD testing
We are presenting 30+ abstracts spanning various areas of oncology at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, May 30 – June 3, 2025 – including 6 oral presentations and 19 posters.
Natera’s Expanded Comprehensive Portfolio ultra-sensitive tumor-informed MRD assays1
- Signatera™ Exome: single-digit ppm detection
- Signatera™ Genome: 1ppm detection, with single-digit ppm LOD95 and Signatera™ Genome (next-gen): 0.1ppm detection
- Latitude™: Tissue-free MRD assay now available for CRC; expanding to breast, lung, and bladder in H2 2025
- Real-world data on >300,000 patients, with multimodal data (incl. T/N WES, WTS, digitized H&E slides), longitudinal ctDNA results, treatment and clinical outcomes, significant representation of early and late stage cancers.
Learn about our expanding body of data in solid tumor malignancies
Natera is a recognized leader in molecular disease management
We offer tumor-informed and tissue-free assays that support diverse clinical development needs across a broad range of tumor types and we have several exciting updates to share around our expanded oncology portfolio.
To learn more about this and other important data as well as how Signatera™ may be used to help answer key clinical questions within your practice
To learn more about our data and how incorporating our MRD testing can enable more efficient trial designs, email us at
Patient Testimonial
With Signatera™, Jason has been able to manage his Stage IV CRC diagnosis, intervene early, fight smarter, and never stop planning for tomorrow. His team has had an edge in catching recurrence earlier—allowing for less invasive treatment plans and more peace of mind. Jason’s journey isn’t just about surviving—it’s about thriving. Watch his story.
Signatera™ is the most comprehensively validated and published MRD assay
Is Signatera right for your patients?
We’re here to help you find out
How can Signatera™ support your clinical trials?
Contact us to learn more
1Natera internal data, as of May 2025